Clinical Implications of MajesTEC-1
Amrita Y. Krishnan, MD, and Binod Dhakal, MD, discuss the clinical implications of data from MajesTEC-1 and provide key takeaways on the evolving relapsed/refractory multiple myeloma treatment landscape.
EP: 1.The Current Treatment Landscape for Relapsed/Refractory Multiple Myeloma
EP: 2.MajesTEC-1: Efficacy and Safety of Teclistamab
EP: 3.Teclistamab Dosing and Adverse Event Prophylaxis Practices
Now Viewing
EP: 4.Clinical Implications of MajesTEC-1
EP: 5.Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma
Video content above is prompted by the following questions:
- Based on the long-term efficacy and safety data presented for teclistamab in the MajesTEC-1 trial, what are your key takeaways or clinical implications for the use of this agent in patients with relapsed/refractory multiple myeloma (R/R MM)?
- Despite the promising results with teclistamab, what potential unmet needs or areas for further research and development remain in the treatment of R/R MM?
Recent Videos
Related Content
